$CHRS
Coherus BioSciences, Inc.

2018 Q4 Form 10-K Financial Statement

#000156459019005470 Filed on February 28, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $33.80M $94.18M $15.00M
YoY Change 125.33% 32.08% -1.96%
% of Gross Profit
Research & Development $26.70M $110.2M $31.50M
YoY Change -15.24% -32.11% -46.61%
% of Gross Profit
Depreciation & Amortization $600.0K $3.200M $900.0K
YoY Change -33.33% -5.88% 12.5%
% of Gross Profit
Operating Expenses $60.50M $204.4M $46.47M
YoY Change 30.21% -12.53% -37.47%
Operating Profit -$204.4M
YoY Change -11.94%
Interest Expense -$2.400M $9.684M -$2.400M
YoY Change 0.0% 1.38% 0.0%
% of Operating Profit
Other Income/Expense, Net $300.0K $4.691M -$200.0K
YoY Change -250.0% 37.89% 100.0%
Pretax Income -$62.60M -$209.4M -$49.10M
YoY Change 27.49% -12.12% -35.31%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$62.60M -$209.3M -$49.07M
YoY Change 27.57% -12.11% -35.37%
Net Earnings / Revenue
Basic Earnings Per Share -$3.22
Diluted Earnings Per Share -$824.8K -$3.22 -$840.8K
COMMON SHARES
Basic Shares Outstanding 65.03M
Diluted Shares Outstanding 65.03M

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.40M $72.40M $126.9M
YoY Change -42.95% -42.95% 1.6%
Cash & Equivalents $72.36M $72.40M $126.9M
Short-Term Investments
Other Short-Term Assets $83.00K $10.40M $142.0K
YoY Change -41.55% -44.09% -95.24%
Inventory $1.659M $1.700M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $84.43M $84.40M $145.5M
YoY Change -41.96% -41.99% -9.92%
LONG-TERM ASSETS
Property, Plant & Equipment $6.660M $6.700M $12.77M
YoY Change -47.86% -47.66% 18.27%
Goodwill $943.0K
YoY Change
Intangibles $2.620M
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.00K $4.800M $800.0K
YoY Change -98.25% 500.0% -57.42%
Total Long-Term Assets $15.03M $15.10M $17.12M
YoY Change -12.2% -11.7% 0.81%
TOTAL ASSETS
Total Short-Term Assets $84.43M $84.40M $145.5M
Total Long-Term Assets $15.03M $15.10M $17.12M
Total Assets $99.47M $99.50M $162.6M
YoY Change -38.83% -38.81% -8.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.29M $15.30M $15.50M
YoY Change -1.33% -1.29% -21.34%
Accrued Expenses $7.008M $17.50M $6.976M
YoY Change 0.46% 105.88% -75.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.26M $33.30M $28.40M
YoY Change 17.14% 17.25% -49.65%
LONG-TERM LIABILITIES
Long-Term Debt $103.1M $103.1M $101.6M
YoY Change 1.48% 1.48% 1.3%
Other Long-Term Liabilities $1.645M $1.700M $2.073M
YoY Change -20.65% -19.05% -17.08%
Total Long-Term Liabilities $1.645M $104.8M $2.073M
YoY Change -20.65% 1.06% -97.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.26M $33.30M $28.40M
Total Long-Term Liabilities $1.645M $104.8M $2.073M
Total Liabilities $138.1M $138.1M $132.1M
YoY Change 4.53% 5.58% -16.41%
SHAREHOLDERS EQUITY
Retained Earnings -$984.8M -$775.5M
YoY Change 26.99%
Common Stock $946.5M $808.1M
YoY Change 17.13%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$38.59M -$38.60M $30.54M
YoY Change
Total Liabilities & Shareholders Equity $99.47M $99.50M $162.6M
YoY Change -38.83% -38.81% -8.9%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$62.60M -$209.3M -$49.07M
YoY Change 27.57% -12.11% -35.37%
Depreciation, Depletion And Amortization $600.0K $3.200M $900.0K
YoY Change -33.33% -5.88% 12.5%
Cash From Operating Activities -$47.40M -$159.3M -$29.90M
YoY Change 58.53% -20.48% -65.55%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K $789.0K -$100.0K
YoY Change 100.0% -82.75% -97.22%
Acquisitions
YoY Change
Other Investing Activities $16.00M -$400.0K $14.50M
YoY Change 10.34% -300.0%
Cash From Investing Activities $15.80M -$1.188M $14.40M
YoY Change 9.72% -73.1% -500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.600M 105.4M 6.900M
YoY Change -62.32% -49.02% -87.68%
NET CHANGE
Cash From Operating Activities -47.40M -159.3M -29.90M
Cash From Investing Activities 15.80M -1.188M 14.40M
Cash From Financing Activities 2.600M 105.4M 6.900M
Net Change In Cash -29.00M -54.57M -8.600M
YoY Change 237.21% -2878.26% -75.0%
FREE CASH FLOW
Cash From Operating Activities -$47.40M -$159.3M -$29.90M
Capital Expenditures -$200.0K $789.0K -$100.0K
Free Cash Flow -$47.20M -$160.1M -$29.80M
YoY Change 58.39% -21.87% -64.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
72356000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
126911000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
50000
CY2017Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
60000
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2379000
CY2017Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
3395000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
83000
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
142000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
84433000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
145477000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6660000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12773000
CY2018Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
4012000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2620000
CY2018Q4 us-gaap Goodwill
Goodwill
943000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
785000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14000
CY2018Q4 us-gaap Assets
Assets
99467000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
15294000
CY2017Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
233000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10540000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2074000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7008000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6976000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
77319000
CY2017Q4 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
25402000
CY2018Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
0
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
908000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59840467
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59840467
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2017 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2016 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:LicenseAndServiceMember
CY2018 chrs Other Revenues
OtherRevenues
0
CY2017 chrs Other Revenues
OtherRevenues
0
CY2016 chrs Other Revenues
OtherRevenues
630000
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Revenues
Revenues
1556000
CY2016 us-gaap Revenues
Revenues
190106000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
71303000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
51597000
CY2015Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-6929000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3312000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27421000
CY2016 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
451000
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19354000
CY2017 chrs Offering Costs Associated With Common Stock Offering And Private Placement
OfferingCostsAssociatedWithCommonStockOfferingAndPrivatePlacement
619000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
33397000
CY2017 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
116000
CY2018 chrs Offering Costs Associated With Common Stock Offering
OfferingCostsAssociatedWithCommonStockOffering
473000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2153000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34984000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1591000
CY2018 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
2130000
CY2018 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
1359000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3235000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3398000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2996000
CY2018 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3230000
CY2017 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-2260000
CY2016 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
4305000
CY2018 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
301000
CY2017 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1352000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
156000
CY2018 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1484000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1041000
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-1300000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
34797000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
33397000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
27421000
CY2017 chrs Non Cash Bonus Payment Settled In Common Stock
NonCashBonusPaymentSettledInCommonStock
2668000
CY2017 chrs Non Cash Manufacturing Postponement Fee Settled In Common Stock
NonCashManufacturingPostponementFeeSettledInCommonStock
4125000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-51000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6000
CY2018 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-3861000
CY2017 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-558000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1859000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
299000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
5484000
CY2018 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7063000
CY2017 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-7788000
CY2016 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
16119000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1016000
CY2017 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-8170000
CY2016 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-19246000
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-130000
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2844000
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1111000
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-88000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-301000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3810000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4965000
CY2018 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-233000
CY2017 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-644000
CY2016 us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-2671000
CY2018 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
8466000
CY2017 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-4871000
CY2016 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
2279000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-9000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-14162000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1674000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
78000
CY2017 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
83000
CY2016 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
65000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1562000
CY2016 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-93236000
CY2017 chrs Increase Decrease In Advance Payments Under License Agreement
IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement
-1070000
CY2016 chrs Increase Decrease In Advance Payments Under License Agreement
IncreaseDecreaseInAdvancePaymentsUnderLicenseAgreement
-260000
CY2016 chrs Increase Decrease In Contingent Liability To Collaborator
IncreaseDecreaseInContingentLiabilityToCollaborator
-66255000
CY2018 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-428000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
242000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
128000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159266000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-200286000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-252545000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
789000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4573000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6515000
CY2018 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
42869000
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
74344000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
43170000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
74500000
CY2018 us-gaap Payments To Acquire Interest In Subsidiaries And Affiliates
PaymentsToAcquireInterestInSubsidiariesAndAffiliates
300000
CY2018 chrs Payments To Acquire Interest In Related Party
PaymentsToAcquireInterestInRelatedParty
400000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1188000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4417000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6515000
CY2016 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
75000000
CY2016 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
25000000
CY2017 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
75000000
CY2018 chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
101748000
CY2017 chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
131305000
CY2016 chrs Proceeds From Issuance Common Stock Offering Net Of Underwriters Discounts Commissions And Offering Costs
ProceedsFromIssuanceCommonStockOfferingNetOfUnderwritersDiscountsCommissionsAndOfferingCosts
123606000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
739000
CY2018 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1591000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2082000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
482000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3312000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105421000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
206787000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
226179000
CY2018 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
468000
CY2017 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-120000
CY2016 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-398000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54565000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1964000
CY2016 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33279000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
127756000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125792000
CY2015Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
159071000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
8200000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
8200000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
6939000
CY2018 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
194000
CY2017 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
-430000
CY2016 chrs Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
507000
CY2018 chrs Non Cash Minority Interest Reflected In Additional Paid In Capital
NonCashMinorityInterestReflectedInAdditionalPaidInCapital
1359000
CY2018 chrs Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
-39000
CY2017 chrs Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
75000
CY2016 chrs Common Stock Offering Costs Included In Accounts Payable And Accrued Liabilities
CommonStockOfferingCostsIncludedInAccountsPayableAndAccruedLiabilities
39000
CY2017 chrs Manufacturing Services Settled In Common Stock
ManufacturingServicesSettledInCommonStock
6810000
CY2018 us-gaap Nature Of Operations
NatureOfOperations
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9.5pt;"><a name="Notes_to_Consolidated"></a><a name="Notes_to_Consolidated"></a>Organization and Operations </p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is a commercial-stage biotherapeutics company, focused on the global biosimilar market. Biosimilars are a class of protein-based therapeutics with high similarity to approved originator products on the basis of various structural, physicochemical and biological properties, as well as in terms of safety and efficacy. The Company&#8217;s headquarters and laboratories are located in Redwood City, California and in Camarillo, California, respectively.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 25, 2018, the Company received regulatory approval for the marketing of UDENYCA&#8482; (pegfilgrastim-cbqv), a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor, from the European Commission, and received regulatory approval for UDENYCA&#8482; from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on November 2, 2018. The Company initiated U.S. sales of UDENYCA&#8482; on January 3, 2019.</p> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Need to Raise Additional Capital </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2018, the Company had an accumulated deficit of $984.8 million and cash and cash equivalents of $72.4&#160;million. In 2018, the Company issued and sold 1,799,504 shares of common stock at a weighted average price of $12.14 per share through its ATM Offering Program and received total net proceeds of $21.0 million after deducting the underwriting discounts and commissions and offering expenses. In May 2018, the Company completed an underwritten public offering of 5,948,274 shares of its common stock at a price to the public of $14.50 per share, which includes the closing of the full exercise of the underwriters&#8217; option to purchase an additional 775,861 shares of common stock. The Company received net proceeds from the offering of $80.8 million, after deducting the underwriting discounts and commissions and offering expenses (see Note 9). The Company also entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with affiliates of Health Royalty Partners consisting of a six-year term loan facility for an aggregate principal of $75.0 million in January 2019. The Company believes that its current available cash and cash equivalents, the proceeds from the Credit Agreement of $73.1 million, net of offering and original issue discount costs, and cash collected from UDENYCA&#8482; sales will be sufficient to fund its planned expenditures and meet the Company&#8217;s obligations for at least 12 months following its financial statement issuance date<font style="color:#1F497D;">. </font>The Company may need to raise additional funds in the future; however there can be no assurance that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable. If the Company is unable to obtain adequate financing when needed, it may have to delay, reduce the scope of or suspend one or more of its clinical trials, or research and development programs. </p>
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. Management uses significant judgment when making estimates related to its stock-based compensation, valuation of deferred tax assets, impairment of goodwill and long-lived assets, the valuation of acquired intangible assets, valuation and reserves for inventory, clinical trial accruals, revenue recognition periods, contingent consideration, convertible notes valuation, as well as certain accrued liabilities. Management bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Accounting estimates and judgements are inherently uncertain and the actual results could differ from these estimates. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk </p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains its cash in bank accounts, which at times exceed federally insured limits. The Company attempts to minimize the risks related to cash, cash equivalents and restricted cash by investing in money markets with a broad and diverse range of financial instruments. The investment portfolio is maintained in accordance with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company also maintains restricted cash in money market funds that invest primarily in U.S. Treasury securities. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash and money market funds. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a strategic commercial supply agreement with KBI Biopharma (&#8220;KBI&#8221;) for the supply of <font style="color:#000000;">UDENYCA&#8482;. The Company currently has not engaged back-up suppliers or vendors for this single-sourced service. If KBI is not able to manufacture the supply needed in the quantities and timeframe required, the Company may not be able to supply the </font>product in a timely manner.</p>
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
52000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-571000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53000
CY2018 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2018 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2800000
CY2017 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0
CY2016 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
0
CY2018 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
less than a 50%
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19261805
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16027317
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14624007
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Into Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2017 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Out Of Level3
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersOutOfLevel3
0
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2851000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1576000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1244000
CY2018Q4 us-gaap Inventory Gross
InventoryGross
5671000
CY2018Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
5671000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19697000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22575000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13037000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9802000
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
3900000
CY2017 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
600000
CY2018Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
3950000
CY2017Q4 chrs Accrued Clinical And Manufacturing Liabilities Current
AccruedClinicalAndManufacturingLiabilitiesCurrent
5462000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3058000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1004000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1556000
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
189476000
CY2017Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1395000
CY2015Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
40341
CY2018 chrs Number Of Laboratory Facility Structure
NumberOfLaboratoryFacilityStructure
2
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6422000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
27070000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2672000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2518000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
38682000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2200000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
2300000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1700000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11406219
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4963100
CY2018 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
477019
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1217747
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14674553
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.321
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.971
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.513
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
19.389
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.202
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
14674553
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
8531888
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14.202
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
13.969
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y2M23D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M23D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y1M9D
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22368000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
22368000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
22365000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
29900
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
29400
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
23200
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.77
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.70
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.32
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4900000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2100000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15800000
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
49700000
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
34797000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33397000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
27421000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Expected Dividend
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend
0
CY2017Q2 us-gaap Restructuring Charges
RestructuringCharges
3600000
CY2018Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
2100000
CY2018Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2018 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentDomestic
-208843000
CY2017 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentDomestic
-222674000
CY2016 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentDomestic
-95776000
CY2018 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentForeign
-496000
CY2017 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentForeign
-15496000
CY2016 chrs Income Loss From Continuing Operations Before Income Taxes Attributable To Parent Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesAttributableToParentForeign
-31561000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0016
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0080
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
13119000
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0198
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0005
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0221
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0843
CY2018 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0015
CY2017 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0019
CY2016 chrs Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.0202
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0261
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0210
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0838
CY2018 chrs Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate
0.00
CY2017 chrs Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate
-0.3690
CY2016 chrs Effective Income Tax Rate Reconciliation Change In Tax Reform Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInTaxReformTaxRate
0.00
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.0223
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0021
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0013
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2610
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.0194
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3378
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
168753000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
134420000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
39891000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
34435000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
7901000
CY2017Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
336000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
17123000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
3942000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
655000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
237610000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
182965000
CY2018Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
552000
CY2017Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
550000
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
552000
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
550000
CY2018Q4 chrs Deferred Tax Asset Liability Net
DeferredTaxAssetLiabilityNet
237058000
CY2017Q4 chrs Deferred Tax Asset Liability Net
DeferredTaxAssetLiabilityNet
182415000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
237058000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
182415000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2018 chrs Tax Cuts And Jobs Act Of2017 Change In Tax Rate Gross Increase Of Deferred Tax Asset
TaxCutsAndJobsActOf2017ChangeInTaxRateGrossIncreaseOfDeferredTaxAsset
2900000
CY2018 chrs Tax Cuts And Jobs Act Of2017 Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
87900000
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
54600000
CY2017 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4600000
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
43000000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
15682000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18682000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10605000
CY2018 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1276000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3387000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6111000
CY2018 chrs Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
1157000
CY2017 chrs Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
-6387000
CY2016 chrs Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
1966000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
18115000
CY2018 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2016 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
42032000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
44910000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
56972000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
60502000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-44302000
CY2018Q2 us-gaap Profit Loss
ProfitLoss
-43685000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-58826000
CY2018Q4 us-gaap Profit Loss
ProfitLoss
-62596000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-44297000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-43638000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-58808000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-62596000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.74
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.87
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.92
CY2017Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
161000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
72578000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
58033000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
56615000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
46466000
CY2017Q1 us-gaap Profit Loss
ProfitLoss
-74822000
CY2017Q2 us-gaap Profit Loss
ProfitLoss
-55402000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-58993000
CY2017Q4 us-gaap Profit Loss
ProfitLoss
-49069000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-74778000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-55336000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-58989000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-49067000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.08
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84

Files In Submission

Name View Source Status
0001564590-19-005470-index-headers.html Edgar Link pending
0001564590-19-005470-index.html Edgar Link pending
0001564590-19-005470.txt Edgar Link pending
0001564590-19-005470-xbrl.zip Edgar Link pending
chrs-10k_20181231.htm Edgar Link pending
chrs-20181231.xml Edgar Link completed
chrs-20181231.xsd Edgar Link pending
chrs-20181231_cal.xml Edgar Link unprocessable
chrs-20181231_def.xml Edgar Link unprocessable
chrs-20181231_lab.xml Edgar Link unprocessable
chrs-20181231_pre.xml Edgar Link unprocessable
chrs-ex231_6.htm Edgar Link pending
chrs-ex311_8.htm Edgar Link pending
chrs-ex312_7.htm Edgar Link pending
chrs-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gdfehkvh0x2q000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending